A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia. — OLIMPIC  

Choroidal Neovascularization Secondary to Pathologic Myopia Clinical Trial

Official title: A 12-month, Open-label, Interventional, Multicentre Study to Investigate the Current Criteria Driving Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Status Completed

Clinical Trial Summary

The primary objective of the study was to investigate current criteria driving re-treatment in patients affected by Choroidal Neovascularization (CNV) secondary to Pathologic Myopia (PM) and experiencing a relapse of the disease after the first administration of ranibizumab.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Choroidal Neovascularization
• Choroidal Neovascularization Secondary to Pathologic Myopia
• Myopia
• Neoplasm Metastasis
• Neovascularization, Pathologic
• Vision Disorders
• Vision, Low

• NCT number: NCT02034006
• Study type: Interventional
• Source: Novartis
• Status: Completed
• Phase: Phase 3
• Start date: June 10, 2014
• Completion date: July 15, 2016